FDA approves Alzheimer’s drug lecanemab amid safety concerns

Lecanemab in early Alzheimer's disease

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Swanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847

Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches?

Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03163-y · Cited by 81

Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases

Rhea, E. M., Babin, A., Thomas, P., Omer, M., Weaver, R., Hansen, K., Banks, W. A., & Talbot, K. (2024) · Tissue Barriers · doi:10.1080/21688370.2023.2292461 · Cited by 81

Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?

Melchiorri, D., Merlo, S., Micallef, B., Borg, J.-J., & Dráfi, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1196413 · Cited by 73

Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting

Zeng, X., Chen, Y., Sehrawat, A., Lee, J., Lafferty, T. K., Kofler, J., Berman, S., Sweet, R. A., Tudorascu, D., Klunk, W. E., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00711-1 · Cited by 79

The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells

Cai, W., Wu, T., & Chen, N. (2023) · Biomolecules · doi:10.3390/biom13020313 · Cited by 69

Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center

Shields, L. B. E., Hust, H. S., Cooley, S. D., Cooper, G. E., Hart, R. N., Dennis, B. C., Freeman, S. W., Cain, J., Shang, W. Y., Wasz, K. M., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.159 · Cited by 57

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56

Molecular insights into the pathogenic impact of vitamin D deficiency in neurological disorders

Anwar, M. J., Alenezi, S. K., & Alhowail, A. H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114718 · Cited by 60

Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy

de Kort, A. M., Kuiperij, H. B., Marques, T. M., Jäkel, L., van den Berg, E., Kersten, I., van Berckel‐Smit, H. E. P., Duering, M., Stoops, E., Abdo, W. F., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26610 · Cited by 49

Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer’s Disease

Vrabec, R., Blunden, G., & Cahlíková, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054399 · Cited by 50

In 2024, the amyloid-cascade-hypothesis still remains a working hypothesis, no less but certainly no more

Behl, C. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1459224 · Cited by 57

Enhancing the Therapeutic Effect in Alzheimer's Disease Drugs: The role of Polypharmacology and Cholinesterase inhibitors

Martins, M. M., Branco, P. S., & Ferreira, L. M. (2023) · ChemistrySelect · doi:10.1002/slct.202300461 · Cited by 50

A Nanozyme-Boosted MOF-CRISPR Platform for Treatment of Alzheimer’s Disease

Yang, J., Qin, G., Liu, Z., Zhang, H., Du, X., Ren, J., & Qu, X. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02272 · Cited by 43

Gut-brain axis: gut dysbiosis and psychiatric disorders in Alzheimer’s and Parkinson’s disease

Denman, C. R., Park, S. M., & Jo, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1268419 · Cited by 45

The multiple roles of chronic stress and glucocorticoids in Alzheimer's disease pathogenesis

Burke, M. R., Sotiropoulos, I., & Waites, C. L. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.08.015 · Cited by 43

Biomarkers for Managing Neurodegenerative Diseases

Cheslow, L., Snook, A. E., & Waldman, S. A. (2024) · Biomolecules · doi:10.3390/biom14040398 · Cited by 41

The Vascular-Immune Hypothesis of Alzheimer’s Disease

Mehta, R. I., & Mehta, R. I. (2023) · Biomedicines · doi:10.3390/biomedicines11020408 · Cited by 39

Prevention and Treatment Strategies for Alzheimer’s Disease: Focusing on Microglia and Astrocytes in Neuroinflammation

Zhang, S.-S., Gao, Z., Feng, L., & Li, M. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s483412 · Cited by 39

Lipid metabolism transcriptomics of murine microglia in Alzheimer’s disease and neuroinflammation

Shippy, D. C., & Ulland, T. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-41897-6 · Cited by 35

Curcumin-derived carbon quantum dots: Dual actions in mitigating tau hyperphosphorylation and amyloid beta aggregation

Lim, J. L., Lin, C., Huang, C., & Chang, L. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113676 · Cited by 34

Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?

Ailioaie, L. M., Ailioaie, C., & Litscher, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030916 · Cited by 40

The 2022 yearbook of Neurorestoratology

Huang, H., Bach, J. R., Sharma, H. S., Saberi, H., Jeon, S. R., Guo, X., Shetty, A. K., Hawamdeh, Z. M., Sharma, A., Wild, K. V., et al. (2023) · Journal of Neurorestoratology · doi:10.1016/j.jnrt.2023.100054 · Cited by 37

Emerging Alzheimer’s disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions

Tobeh, N. S., & Bruce, K. D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1259012 · Cited by 35

Lecanemab: More Questions Than Answers!

Kaur, U., Reddy, J., Tiwari, A., Chakrabarti, S., & Chakrabarti, S. S. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01331-1 · Cited by 30

HTRA1 disaggregates α-synuclein amyloid fibrils and converts them into non-toxic and seeding incompetent species

Chen, S., Puri, A., Bell, B., Fritsche, J., Palacios, H. H., Balch, M., Sprunger, M. L., Howard, M. K., Ryan, J. J., Haines, J. N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46538-8 · Cited by 32

The Breakthroughs and Caveats of Using Human Pluripotent Stem Cells in Modeling Alzheimer’s Disease

Bendtsen, K. M., & Hall, V. J. (2023) · Cells · doi:10.3390/cells12030420 · Cited by 30

PCSK9 inhibition attenuates alcohol-associated neuronal oxidative stress and cellular injury

Wagner, J., Park, L. M., Mukhopadhyay, P., Matyas, C., Trojnar, E., Damadzic, R., Jung, J., Bell, A. S., Mavromatis, L. A., Hamandi, A. M., et al. (2024) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2024.04.022 · Cited by 26

Cutting-edge Strategies for Overcoming Therapeutic Barriers in Alzheimer's Disease

Inamdar, A., Gurupadayya, B., Halagali, P., Nandakumar, S., Pathak, R., Singh, H., & Sharma, H. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128344571241018154506 · Cited by 33

Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease

Susmitha, G., & Kumar, R. K. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109478 · Cited by 27

Monoclonal antibodies and aptamers: The future therapeutics for Alzheimer's disease

Barrera-Ocampo, A. A. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.034 · Cited by 30

Neuronanomedicine for Alzheimer’s and Parkinson’s disease: Current progress and a guide to improve clinical translation

Boyton, I., Valenzuela, S. M., Collins‐Praino, L. E., & Care, A. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.11.004 · Cited by 23

Polysaccharides extracted from common buckwheat (Fagopyrum esculentum) attenuate cognitive impairment via suppressing RAGE/p38/NF-κB signaling and dysbiosis in AlCl3-treated rats

Liu, Y.-C., Chen, S.-Y., Chen, Y.-Y., Chang, H., Chiang, I., & Yen, G. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133898 · Cited by 24

Emergence of the brain-border immune niches and their contribution to the development of neurodegenerative diseases

Tan, L. Y., Cunliffe, G., Hogan, M. P., Yeo, X. Y., Oh, C., Jin, B., Kang, J., Park, J., Kwon, M., Kim, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1380063 · Cited by 23

Quinolinetrione-tacrine hybrids as multi-target-directed ligands against Alzheimer's disease

Uliassi, E., Bergamini, C., Rizzardi, N., Naldi, M., Cores, Á., Bartolini, M., Menéndez, J. C., & Bolognesi, M. L. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117419 · Cited by 24

Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023

Martins, A. C., Oshiro, M. Y., Alberício, F., & de la Torre, B. G. (2024) · Biomedicines · doi:10.3390/biomedicines12091992 · Cited by 25

Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion

Esquer, A., Blanc, F., & Collongues, N. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00541-1 · Cited by 25

Alzheimer's Disease and Frontotemporal Dementia: A Review of Pathophysiology and Therapeutic Approaches

Kelliny, S., Zhou, X., & Bobrovskaya, L. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70046 · Cited by 27

Improved prebiotic-based “shield” equipped probiotics for enhanced colon cancer therapy by polarizing M1 macrophages and regulating intestinal microbiota

Wang, Y., Su, X., Liu, Y., Hu, L., Lin, K., Xu, C., Sun, Z., Sun, C., Guo, H., & Shen, S. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.040 · Cited by 21

Changes of tRNA-Derived Fragments by Alzheimer’s Disease in Cerebrospinal Fluid and Blood Serum

Wu, W., Shen, A., Lee, I., Miranda-Morales, E. G., Spratt, H. M., Pappolla, M. A., Fang, X., & Bao, X. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230412 · Cited by 20

Glycolytic dysregulation in Alzheimer’s disease: unveiling new avenues for understanding pathogenesis and improving therapy

Wu, Y., Yang, L., Jiang, W., Zhang, X., & Yao, Z. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00190 · Cited by 19

Advances in PET imaging of protein aggregates associated with neurodegenerative disease

Higuchi, M., Tagai, K., Takahata, K., & Endo, H. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01126-2 · Cited by 21

Recent progress of small-molecule-based theranostic agents in Alzheimer's disease

Gao, F., Chen, J., Zhou, Y., Cheng, L., Hu, M., & Wang, X. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00330b · Cited by 18

Multi-target potential of newly designed tacrine-derived cholinesterase inhibitors: Synthesis, computational and pharmacological study

Jevtić, I. I., Suručić, R. V., Tovilović-Kovačević, G., Zogovic, N. S., Kostić‐Rajačić, S., Andrić, D. B., & Penjišević, J. Z. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117649 · Cited by 18

The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials

Abdelazim, K., Allam, A. A., Afifi, B., Abdulazeem, H. M., & Elbehiry, A. I. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07477-w · Cited by 18

Alzheimer’s disease basics: we all should know

Das, S. K. (2025) · Neurological Research · doi:10.1080/01616412.2025.2529560 · Cited by 19

Δ8-THC Protects against Amyloid Beta Toxicity Modulating ER Stress In Vitro: A Transcriptomic Analysis

Gugliandolo, A., Blando, S., Salamone, S., Caprioglio, D., Pollastro, F., Mazzon, E., & Chiricosta, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076598 · Cited by 18

Prevalence of Cerebral Amyloid Angiopathy Pathology and Strictly Lobar Microbleeds in East-Asian Versus Western Populations: A Systematic Review and Meta-Analysis

de Kort, A. M., Verbeek, M. M., Schreuder, F. H. B. M., Klijn, C. J. M., & Jäkel, L. (2024) · Journal of Stroke · doi:10.5853/jos.2023.04287 · Cited by 17

Exploring Peptido‐Nanocomposites in the Context of Amyloid Diseases

Andrikopoulos, N., Tang, H., Wang, Y., Liang, X., Li, Y., Davis, T. P., & Ke, P. C. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202309958 · Cited by 15

A randomized feasibility trial of the modified Atkins diet in older adults with mild cognitive impairment due to Alzheimer’s disease

Buchholz, A. S., Deme, P., Betz, J., Brandt, J., Haughey, N. J., & Cervenka, M. C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1182519 · Cited by 19

Refining the interactions between microglia and astrocytes in Alzheimer’s disease pathology

Chen, J., Xu, S., Wang, L., Liu, X., Liu, G., Tan, Q., Li, W., Zhang, S., & Du, Y. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.033 · Cited by 17

Inhibition of Amyloid β Aggregation and Cytotoxicity by Berbamine Hydrochloride

Dong, L., Xie, H., Jia, L., Hong, L., & Gao, L. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202301865 · Cited by 14

Lecanemab: A hope in the management of Alzheimer’s disease

Thakkar, N., Martis, P. B., Kutikuppala, L. V. S., Kuchana, S. K., & Mohapatra, R. K. (2023) · Brain Circulation · doi:10.4103/bc.bc_10_23 · Cited by 14

Long-term normalization of calcineurin activity in model mice rescues Pin1 and attenuates Alzheimer’s phenotypes without blocking peripheral T cell IL-2 response

Stallings, N. R., O’Neal, M. A., Hu, J., Shen, Z., & Malter, J. S. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01323-5 · Cited by 14

Hesperidin Methyl Chalcone reduces extracellular Aβ(25-35) peptide aggregation and fibrillation and also protects Neuro 2a cells from Aβ(25-35) induced neuronal dysfunction

Jafni, S., Sathya, S., Arunkumar, M., Kiruthiga, C., Jeyakumar, M., Murugesh, E., & Devi, K. P. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117536 · Cited by 14

Structure-based design of multitargeting ChEs-MAO B inhibitors based on phenyl ring bioisosteres: AChE/BChE selectivity switch and drug-like characterization.

Spada, G. L., Miniero, D. V., Rullo, M., Cipolloni, M., Delre, P., Colliva, C., Colella, M., Leonetti, F., Liuzzi, G., Mangiatordi, G., et al. (2024) · European journal of medicinal chemistry · doi:10.1016/j.ejmech.2024.116511 · Cited by 14

Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies

Uliassi, E., Bolognesi, M. L., & Milelli, A. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00733 · Cited by 13

Progress in precision drug delivery systems for neurodegenerative diseases with muscle atrophy

Zhang, G., Hu, F., Zhang, Y., Li, D., Deng, Y., Yang, M., Huang, T., Deng, X., Li, Y., Fu, C., et al. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111027 · Cited by 16

Non-invasive biomarkers for mild cognitive impairment and Alzheimer's disease

Botello‐Marabotto, M., Martínez‐Bisbal, M. C., Calero, M., Bernardos, A., Pastor, A. B., Medina, M., & Martínez‐Máñez, R. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106312 · Cited by 12

A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer’s disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial

Henry, D. S., & Pellegrino, R. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292863 · Cited by 12

Dual inhibition of butyrylcholinesterase and p38α mitogen-activated protein kinase: A new approach for the treatment of Alzheimer's disease

Benetik, S. F., Knez, D., Obreza, A., Košak, U., & Gobec, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108748 · Cited by 14

Cerebral to Systemic Representations of Alzheimer’s Pathogenesis Stimulated by Polystyrene Nanoplastics

Wang, Y., Liang, X., Andrikopoulos, N., Zheng, S., Li, Y., & Ke, P. C. (2025) · Environment & Health · doi:10.1021/envhealth.5c00160 · Cited by 12

Novel drug-like fluorenyl derivatives as selective butyrylcholinesterase and β-amyloid inhibitors for the treatment of Alzheimer’s disease

Pasieka, A., Panek, D., Zaręba, P., Sługocka, E., Gucwa, N., Espargaró, A., Latacz, G., Khan, N., Bucki, A., Sabaté, R., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117333 · Cited by 12

Monoclonal antibodies for the management of central nervous system diseases: clinical success and future strategies

Gautam, A. S., Pandey, S. K., Lasure, V., Dubey, S., & Singh, R. K. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2227378 · Cited by 12

Clinical Characteristics, Neuroimaging Markers, and Outcomes in Patients with Cerebral Amyloid Angiopathy: A Prospective Cohort Study

Theodorou, A., Palaiodimou, L., Papagiannopoulou, G., Kargiotis, O., Psychogios, K., Safouris, A., Bakola, E., Chondrogianni, M. E., Kotsali-Peteinelli, V., Melanis, K., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175591 · Cited by 11

Advances in Understanding and Managing Alzheimer's Disease: From Pathophysiology to Innovative Therapeutic Strategies

Rathee, S., Sen, D., Pandey, V., & Jain, S. (2024) · Current Drug Targets · doi:10.2174/0113894501320096240627071400 · Cited by 16

Disrupted mitochondrial response to nutrients is a presymptomatic event in the cortex of the APPSAA knock‐in mouse model of Alzheimer's disease

Norambuena, A., Sagar, V. K., Wang, Z., Raut, P., Feng, Z., Wallrabe, H., Pardo, E., Kim, T., Alam, S. R., Hu, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14144 · Cited by 10

Cerebral biomimetic nano-drug delivery systems: A frontier strategy for immunotherapy

Tian, H., Yao, J., Ba, Q., Meng, Y., Cui, Y., Quan, L., Gong, W., Wang, Y., Yang, Y., Yang, M., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.058 · Cited by 12

Proteomics revealed an association between ribosome-associated proteins and amyloid beta deposition in Alzheimer's disease

Feng, L., Wang, G., Song, Q., Feng, X., Su, J., Ji, G., & Li, M. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01330-3 · Cited by 11

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

Hu, H., Zhao, Y., Mao, J., He, J., Zhang, Y., Ye, H., & Yang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1561020 · Cited by 11

Deciphering mechanisms of action of ACE inhibitors in neurodegeneration using Drosophila models of Alzheimer’s disease

Ghalayini, J., & Boulianne, G. L. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1166973 · Cited by 10

Novel Development and Prospects in Pathogenesis, Diagnosis, and Therapy of Alzheimer’s Disease

Teng, Z. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230130 · Cited by 10

Study on the effect of 40 Hz non-invasive light therapy system. A protocol for a randomized, double-blinded, placebo-controlled clinical trial

Agger, M. P., Horning, M., Carstensen, M. S., Danielsen, E. R., Baandrup, A. O., Nguyen, M., Høgh, P., Miskowiak, K. W., Petersen, P. M., Madsen, K. H., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1250626 · Cited by 9

Protein kinases as therapeutic targets for Alzheimer’s disease: a brief review

Silva, I. M. F., Franco, G. D. R. R., Gontijo, V. S., & Viegas, C. (2024) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.00092 · Cited by 9

Derivatives of 9-phosphorylated acridine as butyrylcholinesterase inhibitors with antioxidant activity and the ability to inhibit β-amyloid self-aggregation: potential therapeutic agents for Alzheimer’s disease

Makhaeva, G., Kovaleva, N., Rudakova, E., Boltneva, N., Lushchekina, S., Astakhova, T., Timokhina, E., Serebryakova, O., Shchepochkin, A. V., Averkov, M. A., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1219980 · Cited by 9

Exploration of the novel phthalimide-hydroxypyridinone derivatives as multifunctional drug candidates against Alzheimer’s disease

Zhu, X., Lv, Y., Fan, M., Guo, J., Zhang, Y., Gao, B., Zhang, C., & Xie, Y. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106817 · Cited by 9

Effects of Serious Games in Older Adults With Mild Cognitive Impairment

Wang, S., Kang, D. W., Um, Y. H., Kim, S., Lee, S., Lee, C. U., & Lim, H. K. (2024) · Psychiatry Investigation · doi:10.30773/pi.2023.0308 · Cited by 9

A Systematic Online Living Evidence Summary of experimental Alzheimer’s disease research

Hair, K., Wilson, E., Maksym, O., Macleod, M. R., & Sena, E. S. (2024) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2024.110209 · Cited by 10

Novel tacrine-based multi-target directed Ligands: Enhancing cholinesterase inhibition, NMDA receptor antagonism, and CNS bioavailability for Alzheimer's disease treatment

Svobodová, B., Moravcová, Z., Misiachna, A., Nováková, G., Marek, A., Finger, V., Odvarkova, J., Pejchal, J., Karasová, J. Ž., Netolický, J., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117678 · Cited by 10

Structure-based discovery of forsythoside A as an effective inhibitor to reduce the neurotoxicity of amyloid β

Bai, S., Wang, Y., Ye, W.-L., Wu, S.-Y., Jia, L., Hong, L., Xie, H., & Gao, L. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01587-y · Cited by 8

Bioactivated Glucoraphanin Improves Cell Survival, Upregulating Phospho-AKT, and Modulates Genes Involved in DNA Repair in an In Vitro Alzheimer’s Disease Model: A Network-Transcriptomic Analysis

Minuti, A., Mazzon, E., Iori, R., Chiricosta, L., & Artimagnella, O. (2024) · Nutrients · doi:10.3390/nu16234202 · Cited by 9

Amyloid Imaging–Based Food and Drug Administration Approval of Lecanemab to Treat Alzheimer Disease—What Lasts Long Finally Becomes Good?

Barthel, H. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265667 · Cited by 8

Investigation of Novel Aronia Bioactive Fraction-Alginic Acid Nanocomplex on the Enhanced Modulation of Neuroinflammation and Inhibition of Aβ Aggregation

Jang, B.-K., Shin, S. J., Park, H. H., Kumar, V., Park, Y., Kim, J. Y., Kang, H., Park, S. Y., Kwon, Y., Shin, S.-E., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010013 · Cited by 7

Advances of therapeutic strategies for Alzheimer’s disease

Guo, X., Yue, R.-Z., Cui, Z., Wang, S., Jia, T., Li, W., Zhang, W., Shan, L., & Li, C. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13456-8 · Cited by 9

The Role of Bacopa monnieri in Alzheimer’s Disease: Mechanisms and Potential Clinical Use—A Review

Wiciński, M., Fajkiel-Madajczyk, A., Wójcicki, J., Ozorowski, M., & Szambelan, M. (2025) · Nutrients · doi:10.3390/nu17223538 · Cited by 7

P2Y1 receptor in Alzheimer’s disease

Luo, S., Wang, Y., & Hisatsune, T. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02103 · Cited by 8

Quality by design endorsed fabrication of xanthohumol loaded solid nanostructured lipid carrier based powder for effective treatment of Alzheimer's disease in rats

Khandale, N. B., Birla, D., Alam, M. S., Bashir, B., Vishwas, S., Kumar, A., Potale, Y., Gupta, G., Negi, P., Alam, A., et al. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106792 · Cited by 7

Therapeutic approaches using natural substances on the streptozotocin-induced animal model of sporadic Alzheimer’s disease: a systematic review

Alexandre-Silva, V., Pereira, G. C., & Ribeiro, A. M. (2023) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-023-00696-0 · Cited by 7

Probing the interactions between amyloidogenic proteins and bio-membranes

Ma, L., Li, X., Petersen, R. B., Peng, A., & Huang, K. (2023) · Biophysical Chemistry · doi:10.1016/j.bpc.2023.106984 · Cited by 7

Targeting Neuroinflammation and Cognitive Decline: First-in-Class Dual Butyrylcholinesterase and p38α Mitogen-Activated Protein Kinase Inhibitors

Benetik, S. F., Proj, M., Knez, D., Košak, U., Meden, A., Krajšek, K., Pišlar, A. H., Horvat, S., Švajger, U., Tešić, N., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00933 · Cited by 6

CRM197-scaffolded vaccines designed by epitope grafting ameliorate cognitive decline in an Alzheimer's disease model

Cui, W., Wang, Y., Tang, X., Liu, S., Duan, Y., Gu, T., Mao, J., Li, W., Bao, J., & Wei, Z. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136477 · Cited by 7

Bisphosphonates and the risk of dementia in patients with osteoporosis or fragility fracture: A population‐based study in Hong Kong

Sing, C., Chan, K., Chiu, P. K. C., Lau, W. C. Y., Zhang, X., Tan, K. C. B., & Cheung, C. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70503 · Cited by 7

Analysis of Costs for Imaging-Assisted Pharmaceutical Intervention in Alzheimer’s Disease with Lecanemab: Snapshot of the First 3 Years

Perron, J., Scramstad, C., & Ko, J. H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230633 · Cited by 6

Unraveling the dual role of ADAM10: Bridging the gap between cancer and Alzheimer’s disease

Alexandre-Silva, V., & Cominetti, M. R. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111928 · Cited by 7

Inhibition of FAM19A5 restores synaptic loss and improves cognitive function in mouse models of Alzheimer’s diseasePreprint

Kim, H., Yoo, S., Kwak, H., Ma, S., Kim, R., Lee, M., Ha, N., Pyo, S., Kwon, S.-G., Cho, E.-H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.22.568357 · Cited by 6

Leveraging targeted kinase degradation as a novel therapeutic strategy for Alzheimer's disease

Tassinari, E., & Milelli, A. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00681c · Cited by 5

The identification of a Distinct Astrocyte Subtype that Diminishes in Alzheimer’s Disease

Wei, H., Withrow, J. S., Rakshit, J., Amin, F. U., Nahm, J., Mowry, F. E., Mao, Z., Bhattacharjee, M. B., Zhu, J., Yang, Y., et al. (2024) · Aging and Disease · doi:10.14336/ad.2024.0205-1 · Cited by 7

Identification of a specific APOE transcript and functional elements associated with Alzheimer’s disease

Chen, Q., Aguirre, L., Liang, G., Zhao, H., Dong, T., Borrego, F., de Rojas, I., Hu, Q., Reyes, C., Su, L., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00751-7 · Cited by 5

Effect of Low-Frequency, Low-Energy Pulsed Electromagnetic Fields in Neuronal and Microglial Cells Injured with Amyloid-Beta

Merighi, S., Nigro, M., Travagli, A., Fernández, M., Vincenzi, F., Varani, K., Pasquini, S., Borea, P. A., Salati, S., Cadossi, R., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312847 · Cited by 6

Potential molecular mechanisms of tobacco smoke exposure in Alzheimer’s disease

Xie, Y., Yang, M., Wang, H., Chen, Y., Shi, X., Tang, H., & Sun, Q. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149394 · Cited by 6

Phyto-nanotechnology: A novel beneficial strategy for Alzheimer's disease therapy

Ganguly, S. C., Sangram, S., Paul, S., & Kundu, M. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105868 · Cited by 5

Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns

Mahase, E. (2023) · BMJ · doi:10.1136/bmj.p73 · Cited by 43

Heralded Alzheimer’s drug works — but safety concerns loom

Prillaman, M. (2022) · Nature · doi:10.1038/d41586-022-04240-z · Cited by 9

Concerns about the approval of lecanemab for Alzheimer’s disease

Bakchine, S., Colosimo, C., Emilsson, E., Jónsdóttir, S. E., Massacesi, L., Nonino, F., Religa, D., Richard, E., Weydt, P., & Wolters, F. J. (2025) · BMJ · doi:10.1136/bmj.r778 · Cited by 7

Alzheimer’s disease: Lecanemab gets full FDA approval and black box safety warning

Mahase, E. (2023) · BMJ · doi:10.1136/bmj.p1580 · Cited by 46

New Alzheimer Drug Gains Full Approval

Aschenbrenner, D. S. (2023) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000979084.89835.67